Cargando…

Human thyroid tumours, the puzzling lessons from E7 and RET/PTC3 transgenic mice

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Jin, L, Burniat, A, Dumont, J-E, Miot, F, Corvilain, B, Franc, B
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661780/ http://dx.doi.org/10.1038/sj.bjc.6604991

Ejemplares similares

Human thyroid tumours, the puzzling lessons from E7 and RET/PTC3 transgenic mice
por: Jin, L, et al.
Publicado: (2008)

siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma
por: de Martimprey, Henri, et al.
Publicado: (2008)

A study to evaluate association of nuclear grooving in benign thyroid lesions with RET/PTC1 and RET/PTC3 gene translocation
por: Ashwini, Basavaraj Rangalakshmi, et al.
Publicado: (2023)

Assessment of RET/PTC1 and RET/PTC3 rearrangements in fine-needle aspiration biopsy specimens collected from patients with Hashimoto's thyroiditis
por: Cyniak-Magierska, Anna, et al.
Publicado: (2011)

ret/PTC-1 expression alters the immunoprofile of thyroid follicular cells
por: Denning, Karen, et al.
Publicado: (2008)

Radiation exposure, young age, and female gender are associated with high prevalence of RET/PTC1 and RET/PTC3 in papillary thyroid cancer: a meta-analysis
por: Su, Xuan, et al.
Publicado: (2016)

RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma
por: Romei, Cristina, et al.
Publicado: (2012)

RET/PTC and CK19 Expression in Papillary Thyroid Carcinoma and Its Clinicopathologic Correlation
por: Shin, Eunah, et al.
Publicado: (2005)

Expression of Ret/PTC1, -2, -3, -delta3 and -4 in German papillary thyroid carcinoma.
por: Mayr, B., et al.
Publicado: (1998)

DNA Breaks at Fragile Sites Generate Oncogenic RET/PTC Rearrangements in Human Thyroid Cells
por: Gandhi, Manoj, et al.
Publicado: (2010)

Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements
por: Mechler, C, et al.
Publicado: (2001)

Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours.
por: Santoro, M., et al.
Publicado: (1993)

Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model
por: Cahill, Susanne, et al.
Publicado: (2006)

MON-514 Detection of RAS Mutations and RET/PTC Fusions in Thyroid Cancer Using Microfluidic Digital PCR
por: Ylli, Dorina, et al.
Publicado: (2020)

Corrigendum to “How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer”
por: Prazeres, Hugo, et al.
Publicado: (2016)

Concurrent overexpression of RET/PTC1 and TTF1 confers tumorigenicity to thyrocytes
por: Endo, Toyoshi, et al.
Publicado: (2013)

siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma
por: de Martimprey, Henri, et al.
Publicado: (2008)

BRAF(V600E) and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB
por: Zhou, Dehua, et al.
Publicado: (2017)

RET/PTC Rearrangements Are Associated with Elevated Postoperative TSH Levels and Multifocal Lesions in Papillary Thyroid Cancer without Concomitant Thyroid Benign Disease
por: Su, Xuan, et al.
Publicado: (2016)

SAT540 A Case of Simultaneous Medullary Thyroid Cancer (MTC) And Papillary Thyroid Cancer (PTC) In a Patient With Germline RET Mutation
por: Vaghasia, Nishit, et al.
Publicado: (2023)

THE RET/PTC-3 ONCOGENE ACTIVATES CLASSICAL NF-κB BY STABILIZING NIK
por: Neely, Robert J., et al.
Publicado: (2010)

Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC
por: Kim, Young-Rae, et al.
Publicado: (2008)

A Multifocal Pediatric Papillary Thyroid Carcinoma (PTC) Harboring the AGK-BRAF and RET/PTC3 Fusion in a Mutually Exclusive Pattern Reveals Distinct Levels of Genomic Instability and Nuclear Organization
por: Sisdelli, Luiza, et al.
Publicado: (2021)

Effects of siRNA on RET/PTC3 Junction Oncogene in Papillary Thyroid Carcinoma: From Molecular and Cellular Studies to Preclinical Investigations
por: Ali, Hafiz Muhammad, et al.
Publicado: (2014)

The Difference in Clinical Behavior of Gene Fusions Involving RET/PTC Fusions and THADA/IGF2BP3 Fusions in Thyroid Nodules
por: Tali, George, et al.
Publicado: (2023)

TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma
por: Ye, Song, et al.
Publicado: (2022)

Loss of One or Two PATZ1 Alleles Has a Critical Role in the Progression of Thyroid Carcinomas Induced by the RET/PTC1 Oncogene
por: Monaco, Mario, et al.
Publicado: (2018)

miRNA profiling, detection of BRAF V600E mutation and RET-PTC1 translocation in patients from Novosibirsk oblast (Russia) with different types of thyroid tumors
por: Titov, Sergei E., et al.
Publicado: (2016)

RET/PTC rearrangement in papillary thyroid carcinoma arising in malignant struma ovarii with abdominal wall metastasis and cervical thyroid gland: a case report and review of the literature
por: Kabootari, Maryam, et al.
Publicado: (2023)

Corrigendum to: Interaction of transcription factor AP‐2 gamma with proto‐oncogene PELP1 promotes tumorigenesis by enhancing RET signaling
Publicado: (2021)

Effect of Interferon-γ on the Basal and the TNFα-Stimulated Secretion of CXCL8 in Thyroid Cancer Cell Lines Bearing Either the RET/PTC Rearrangement Or the BRAF V600e Mutation
por: Rotondi, Mario, et al.
Publicado: (2016)

SLIT2/ROBO1‐miR‐218‐1‐RET/PLAG1: A new disease pathway involved in Hirschsprung's disease
Publicado: (2020)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

Corrigendum to “There Is No Elevation of Immunoglobulin E Levels in Albanian Patients with Autoimmune Thyroid Diseases”
por: Latifi-Pupovci, Hatixhe, et al.
Publicado: (2022)

BRAF V600E and RET/PTC Promote the Activity of Nuclear Factor-κB, Inflammatory Mediators, and Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Study of 50 Patients in Inner Mongolia
por: Zhou, Dehua, et al.
Publicado: (2018)

Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line
por: Caccia, Dario, et al.
Publicado: (2010)

Intercellular adhesion molecule 1 is a sensitive and diagnostically useful immunohistochemical marker of papillary thyroid cancer (PTC) and of PTC-like nuclear alterations in Hashimoto's thyroiditis
por: ZHANG, KE, et al.
Publicado: (2016)

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
por: Rosen, Ezra Y., et al.
Publicado: (2022)

Objective assessment of tumour response to therapy based on tumour growth kinetics
por: Mehrara, E, et al.
Publicado: (2011)

Destabilizing RET in targeted treatment of thyroid cancers
por: Gild, M L, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hungj53kind5efqosrk5k8du50